What is the current market size and future outlook for the ovarian cancer market?
The ovarian cancer market size has grown exponentially in recent years. It will grow from $3.67 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to increasing number of elderly population, rising incidence of ovarian cancer cases, increasing prevalence of ovarian cancer, rise in government initiatives, growing healthcare spending.
The ovarian cancer market size is expected to see exponential growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to increased research on targeted therapies and personalized medicine, growing geriatric population, rising healthcare awareness, rising ovarian cancer prevalence, rising healthcare expenditures. Major trends in the forecast period include innovative therapies, advancements in radiation therapy, advanced healthcare infrastructure, technological advancements, adoption of novel drugs.
Get Your Free Sample of The Global Ovarian Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21240&type=smp
How has the ovarian cancer market evolved, and what factors have shaped its growth?
The increasing female population is expected to propel the growth of the ovarian cancer market going forward. The female population refers to the total number of females living in a specific area or worldwide at a given time. The increasing female population is driven by factors such as higher life expectancy, improved healthcare, and demographic shifts. Ovarian cancer treatment supports the female population by offering surgery, chemotherapy, targeted therapy, and immunotherapy to remove cancerous cells, slow disease progression, alleviate symptoms, and improve survival rates, ultimately enhancing quality of life and providing hope for better long-term outcomes. For instance, in March 2024, according to the Census Bureau, a US-based government agency, the United States had a female population of approximately 168 million as of July 2022. Additionally, there were about 1.9 million more females age 85 and older. Furthermore, in December 2022, according to the report published by CEIC Data, a UK-based financial service company, the number of females aged 15-64 was reported at 2,951,856 in 2022, reflecting an increase from 2,940,645 in 2021. Therefore, increasing female population is driving the growth of the ovarian cancer market.
What are the major segments of the ovarian cancer market?
The ovarian cancer market covered in this report is segmented –
1) By Type: Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, Primary Peritoneal Carcinoma
2) By Treatment: Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, Surgery
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-user: Hospitals, Diagnostic Centers, Drug Stores, Online Pharmacies, Other End Users
Subsegments:
1) By Epithelial Ovarian Tumors: Serous Carcinoma, Mucinous Carcinoma, Endometrioid Carcinoma, Clear Cell Carcinoma, Brenner Tumors
2) By Ovarian Germ Cell Tumors: Dysgerminoma, Teratoma, Yolk Sac Tumor, Embryonal Carcinoma, Choriocarcinoma
3) By Ovarian Stromal Tumors: Granulosa Cell Tumors, Thecomas, Sertoli-Leydig Cell Tumors
4) By Primary Peritoneal Carcinoma: High-Grade Serous Carcinoma, Low-Grade Serous Carcinoma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-global-market-report
Which companies dominate the ovarian cancer market?
Major companies operating in the ovarian cancer market are Pfizer Incorporated, Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Novogen Limited, Oasmia Pharmaceutical AB, Clovis Oncology Inc., Aeterna Zentaris Inc., Allarity Therapeutics Inc., Ellipses Pharma Ltd.
How will evolving trends contribute to the growth of the ovarian cancer market?
Major companies operating in the ovarian cancer market are focusing on advanced solutions, such as AI platforms, to analyze complex medical data with accuracy. An AI platform for ovarian cancer is a technology-driven system that leverages artificial intelligence (AI) and machine learning (ML) to enhance various aspects of ovarian cancer care. These platforms typically integrate medical imaging, genomic data, electronic health records (EHRs), and real-time analytics to support early detection, diagnosis, personalized treatment planning, and patient monitoring. For instance, in February 2024, AIIMS Delhi, in collaboration with CDAC Pune, an Indian-based organization, launched iOncology.ai, an indigenously developed AI platform for early detection of breast and ovarian cancer. This platform uses deep learning models to analyze radiological and histopathological images with high accuracy, aiming to improve early diagnosis and survival rates. Already deployed in several hospitals, iOncology.ai integrates with the healthcare system to provide risk assessments and recommend mammograms, particularly for women in rural areas, and is part of a broader initiative to integrate AI into healthcare and reduce pressure on medical systems.
What are the key regional dynamics of the ovarian cancer market, and which region leads in market share?
North America was the largest region in the ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Ovarian Cancer Market Report 2025 Offer?
The ovarian cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Ovarian cancer refers to a type of cancer that originates in the ovaries, which are the female reproductive organs responsible for producing eggs (ova) and hormones such as estrogen and progesterone. It can develop in different parts of the ovaries, including the surface epithelium, the germ cells, or the stroma.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21240
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
